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Abstract
Background: The heterozygous microdeletion of chromosome 22q11.2 results in a spectrum of disorders, including
DiGeorge syndrome (DGS) and velocardiofacial syndrome (VCFS), with phenotypic features that can include the
classic triad of congenital heart disease (CHD), thymic aplasia and hypoparathyroidism. Such microdeletions are
usually detectable by fluorescence in situ hybridization (FISH).
Case presentation: We report a case of a twenty-three year-old female who presented with clinical features of
chromosome 22q11.2 deletion syndrome including cardiac anomalies, hypoparathyroidism and dysmorphic facial
features. FISH did not reveal a 22q11.2 microdeletion. Further genetic analysis showed T box-1 (TBX1) heterozygous
mutation.
Conclusions: The TBX1 gene plays a significant role in the development of fourth pharyngeal arch structures.
Mutations of TBX1, which is found at chromosome 22q11.21 can be responsible for the development of syndromes
classically associated with chromosome 22q11.2 deletions. This case emphasizes that the TBX1 gene, among other
genes, can be responsible for the developmental anomalies seen in these syndromes.
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Background
A wide spectrum of phenotypic features may present as
a result of the deletion of chromosome 22q11.2.
DiGeorge syndrome (DGS), velocardiofacial syndrome
(VCFS), and various other syndromes have been de-
scribed in association with the deletion involving human
chromosome 22q11.2 [1]. The T-box 1 (TBX1) gene, lo-
cated on chromosome 22q11.21, has a significant role in
the differentiation and development of the third and
fourth pharyngeal arches into the pharyngeal arch arter-
ies, cardiac outflow tract, thymus, parathyroid glands,
and craniofacial structures [2–4]. We report a case of a
twenty-three year-old female who presented with pheno-
typic features of 22q11.2 deletion and was found to have
heterozygous mutation of the TBX1 gene.
Case presentation
A twenty three year-old female presented to transition
her care from pediatric to adult endocrinology. At the
age of one year, she had presented to her local emer-
gency department with seizures and was found to have
serum calcium of 6.7 mg/dL (reference range 8.2–10.2
mg/dL). Her serum phosphorus level at that time was
7.8 mg/dL (reference range 2.3–4.7 mg/dL) and magne-
sium of 2.3 mEq/L (reference range 1.5–2.5 mEq/L).
Testing performed at that time included an intact para-
thyroid hormone (PTH) level of 15 pg/mL (reference
range 10–65 pg/mL), a 25-hydroxyvitamin D level of 61
ng/mL (reference range of 30–80 ng/mL) and a 1,25-
dihydroxyvitamin D level of 45 pg/mL (reference range
15–65 pg/mL), consistent with hypocalcemia due to
hypoparathyroidism. There was no history of candidiasis.
By two years old, she was also diagnosed with multiple
other conditions including hydrocephalus, atrial septal
defect, bicuspid aortic valve, left kidney agenesis and
thoracolumbar scoliosis. She was later diagnosed with
learning disabilities including cognitive and attention
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deficits, no other psychiatric disorders were diagnosed.
Her facial features are shown in Fig. 1 and are noticeable
for dysmorphism of the nose, flattened philtrum, micro-
gnathia and hypertelorism (not shown in the figure). She
did not have palatal or teeth abnormalities. She under-
went an immunological evaluation that was unremark-
able. Her biochemical thyroid evaluation was also
normal. Her hypoparathyroidism has been managed with
calcitriol and calcium supplementation. Her corrected
calcium levels were maintained in the range of 8.0–9.5
mg/dL. Her last 24-h urinary calcium was 163.5 mg/dL.
She has not developed nephrolithiasis, and renal ultra-
sound is significant only for an absent left kidney. Given
the clinical features that were compatible with 22q11.2
deletion, she initially underwent FISH that did not reveal
the targeted deletion. She then had bi-directional DNA
sequencing that detected a heterozygous mutation
(c.1055 C > T; p.Pro352Leu) resulting in a proline to leu-
cine substitution at amino acid 352 in the TBX1 gene.
Discussion and conclusions
Chromosome 22q11.2 deletion syndrome accounts for
the most common microdeletion disorder in humans
with an estimated incidence of 1 in 4000–10,000 live
births. [5, 6]. The clinical features of this microdeletion
were first described as a triad of congenital heart disease
(CHD), thymic aplasia and hypoparathyroidism by Dr.
Angelo DiGeorge in 1965. [7, 8]. Other conditions were
subsequently described with overlapping phenotypic fea-
tures including velocardiofacial syndrome (VCFS), cono-
truncal anomaly face syndrome, and Caylercardiofacial
syndrome. [9–11]. It was later concluded that all of these
syndromes share the same causative mutation with
heterogeneous clinical presentations.
The majority of patients have a 3 Mega-base (Mb)
heterozygous deletion of 22q11.2 segment that con-
tains approximately 30 genes responsible for the early
development of the pharyngeal arch derivatives, lead-
ing to compromised maturity of the craniofacial
structures, the upper thorax, the thymus, the parathy-
roid glands, the heart, and the cardiac outflow tract
[12–14]. A wide spectrum of clinical manifestations is
observed including cardiac anomalies, immunodefi-
ciency due to thymic aplasia, hypocalcemia due to
hypoparathyroidism and dysmorphic facial features.
Other findings include palatal, musculoskeletal, gastro-
intestinal, renal, behavioral, psychiatric (including anxiety
and schizophrenia) and cognitive abnormalities (including
learning disabilities, attention-deficit, and mental retard-
ation) were also found to be related [15–17]. The clinical
presentation of the patient reported here was compatible
with the phenotypic features described. Her FISH analysis
did not detect the expected deletion. Classically, FISH has
been the routine diagnostic test to reveal such microdele-
tion. However, the reported sensitivity of this test was
nearly 78% by Michaelovsky et al. [18]. Routine FISH
technique uses a probe mapping to the LCR22A–LCR22B
region, thus, deletions outside this region or deletions that
are too small to detect can be left unrevealed [8, 19]. In
the case mentioned here, further genetic analysis revealed
heterozygous mutation of the TBX1 gene (P352L variant).
This variant has not been reported before in this syn-
drome, however, one missense mutation in a nearby resi-
due (G350D) has been reported in association with
cardiovascular defects [20].
The TBX1 gene has been extensively studied in mice;
heterozygous TBX1 deleted mice were found to have
aortic arch defects which represents one of the major
characteristics of the 22q11.2 deletion syndrome [21].
Homozygous deletion of this gene in mice led to a wider
spectrum of phenotypic characteristics including thymus
and parathyroid abnormalities, cardiac outflow tract
anomalies, and craniofacial defects [22, 23]. In human
studies, Yagi et al. performed mutational analysis in pa-
tients with 22q11.2 deletion syndrome features but with-
out the chromosomal deletion; TBX1 heterozygous
mutation was found responsible for major phenotypic
features in this syndrome, predominantly, cardiac and
cardiac outflow tract anomalies [2, 24, 25]. These find-
ings confirmed that TBX1 gene haploinsufficiency
Fig. 1 Facial features of the reported case showing dysmorphism of
the nose, flattened philtrum and micrognathia
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plays a crucial role in the development of the 22q11.2
deletion syndromes.
In such cases, a multidisciplinary approach for manage-
ment is required and depends on the age of presentation
and the spectrum of consequences. Patients with this syn-
drome need individualized and complex medical care with
vigilant recognition of the acute and long-term manifesta-
tions. From an endocrinology point of view, maintaining
calcium homeostasis remains essential to prevent hypocal-
caemia. The lack of PTH results in the under conversion
of vitamin D (25-hydroxyvitamin D) to its active form (1,
25-dihydroxyvitamin D), and thus, low calcium absorp-
tion. Supplementation with calcium and active vitamin D
(i.e. calcitriol) is the cornerstone of management [26, 27].
These patients also lack the effect of the PTH on renal cal-
cium reabsorption. It is therefore preferred to maintain
serum calcium level in the low normal range to prevent
hypercalciuria and the subsequent development of
nephrolithiasis and renal failure [28]. Some patients may
require thiazide diuretics to decrease urinary calcium ex-
cretion [29]. In patients who fail to maintain stable serum
and urinary calcium on calcium and vitamin D supple-
mentation, recombinant PTH can be given as a second
line therapy. Recombinant human PTH (1–84), the native
form of PTH, was approved by the U.S. food and drug ad-
ministration (FDA) in 2015 for use in patients with
chronic hypoparathyroidism. After double-blinded, ran-
domized clinical trial reported a reduction of, or even in-
dependence from, supplemental calcium and calcitriol
with stable serum and urinary calcium levels over 24
weeks [30]. Synthetic PTH (1–34), which is the active
form of PTH and in fact FDA approved for use in osteo-
porosis, also showed favorable effect with improvement of
hypercalciuria when compared to conventional therapy
with calcitriol and calcium [31, 32].
Over the last two decades, studies have revealed the
consequences of TBX1 haploinsufficiency in mice, mim-
icking the phenotypic features seen in 22q11.2 deletion
syndrome. Human studies to date are limited giving the
rarity of such mutations. The case reported here repli-
cates the findings that were observed in previous human
studies and underscores the fact that TBX1 gene muta-
tion plays a key role in the development of this
syndrome.
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